Multiscale virtual screening optimization for shotgun drug repurposing using the CANDO platform
Abstract
Drug repurposing, the practice of utilizing existing drugs for novel clinical indications, has tremendous potential for improving human health outcomes and increasing therapeutic development efficiency. The goal of multidisease multitarget drug repurposing, also known as shotgun drug repurposing, is to develop platforms that assess the therapeutic potential of each existing drug for every clinical indication. Our Computational Analysis of Novel Drug Opportunities (CANDO) platform for shotgun multitarget repurposing implements several pipelines via large scale modelling and simulation of interactions between comprehensive libraries of drugs/compounds and protein structures. In these pipelines, each drug is described by an interaction signature that is then compared to all other signatures that are then sorted and ranked based on similarity. Pipelines within the platform are benchmarked based on their ability to recover known drugs for all indications in our library, and predictions are generated based on the hypothesis that (novel) drugs with similar signatures may be repurposed for the same indication(s). The drug-protein interactions in the platform used to create the drug-proteome signatures may be determined by any screening or docking method but the primary approach used thus far has been an in house similarity docking protocol. In this study, we calculated drug-proteome interaction signatures using the publicly available molecular docking method Autodock Vina and created hybrid decision tree pipelines that combined our original bio- and cheminformatic approach with the goal of assessing and benchmarking their drug repurposing capabilities and performance. The hybrid decision tree pipeline outperformed the corresponding two docking-based pipelines it was synthesized from, yielding an average indication accuracy of 13.3% at the top10 cutoff (the most stringent), relative to 10.9% and 7.1% for its constituent pipelines, and a random control accuracy of 2.2%. We demonstrate that docking based virtual screening pipelines have unique performance characteristics and that the CANDO shotgun repurposing paradigm is not dependent on a specific docking method. Our results also provide further evidence that multiple CANDO pipelines can be synthesized to enhance drug repurposing predictive capability relative to their constituent pipelines. Overall, this study indicates that pipelines consisting of varied docking based signature generation methods can capture unique and useful signal for accurate comparison of drug-proteome interaction signatures, leading to improvements in the benchmarking and predictive performance of the CANDO shotgun drug repurposing platform.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 15
- FWCI
- 1.58
- Field percentile
- top 17%
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fingerprinting CANDO: Increased Accuracy with Structure and Ligand Based Shotgun Drug Repurposing
James Schuler, Ram Samudrala·ACS OmegaPeer-reviewed·Oct 9, 2019
- Exploration of interaction scoring criteria in the CANDO platform
Zackary Falls, William Mangione, … Ram Samudrala·BMC Research NotesPeer-reviewed·Jun 7, 2019
- Identifying protein subsets and features responsible for improved drug repurposing accuracies using the CANDO platform
William Mangione, Ram Samudrala·MoleculesPeer-reviewed·Jan 4, 2019
- cando.py: Open source software for predictive bioanalytics of large scale drug-protein-disease data
William Mangione, Zackary Falls, … Ram Samudrala·Journal of Chemical Information and ModelingPeer-reviewed·Jun 9, 2020
- DRDOCK: A Drug Repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme
Kun-Lin Tsai, Sui‐Yuan Chang, Lee‐Wei Yang·bioRxiv·Jan 31, 2021
- Evaluating Performance of Drug Repurposing Technologies
James Schuler, Zackary Falls, … Ram Samudrala·Drug Discovery TodayPeer-reviewed·Aug 13, 2021